BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Spine Wave, Inc. Announces Growth of Product Portfolio


10/23/2012 8:40:02 AM

SHELTON, CT--(Marketwire - October 23, 2012) - Spine Wave, Inc. today announced the addition of two new offerings within its expandable product portfolio. Spine Wave has completed a definitive agreement to acquire Santa Clara Technology Inc. The versatile technology developed by SCT provides a unique expandable titanium interbody cage platform, which can be used in a variety of clinical applications. Additionally, Spine Wave has initiated the limited market release of the StaXx® XD 15 degrees Lordotic Expandable Device.

"The acquisition of Santa Clara Technology is another step forward in our strategy to broaden our pipeline of innovative and highly differentiated clinical solutions for spine surgery. Their technology complements our existing expandable offerings, while the addition of Hugues Malandain, Santa Clara Technology CEO, strengthens our already accomplished product development team," said John Pafford, Spine Wave Chief Technology Officer. "Santa Clara Technology is a great fit within Spine Wave," said Mr. Malandain. "We wanted to align our novel technologies with a high-growth company that understands the clinical benefits of expandable technologies and Spine Wave is a clear leader in that respect. I look forward to becoming a part of the Spine Wave team."

Additionally, Mr. Pafford commented that "the Company is initiating a limited market release of the StaXx® XD 15 degrees Lordotic Expandable Device to provide spine surgeons with a novel clinical approach to address sagittal balance with a less invasive means to achieving segmental lordosis. We are excited about the potential for this technology and expect full commercialization of this important device in early 2013."

"In 2012 we have been able to achieve significant revenue growth through a rapid expansion of our independent distribution network," said Mark LoGuidice, Spine Wave Chairman and CEO. "Through internal development efforts, the SCT acquisition, and in collaboration with the Memphis based R&D company, MB Innovations, we expect to introduce several important and novel product solutions in 2013 and beyond. The robust R&D pipeline and the continued focus on expanding our distribution channel has us very excited about our future growth opportunities."

About Spine Wave
Spine Wave's product portfolio features many highly differentiated technologies including the flagship product, the StaXx® XD Expandable Device, which has a four year proven track record for posterior surgery. The StaXx® XD family of products includes StaXx® XDL which is intended to be implanted using a lateral surgical approach. In addition to the expandable technologies, the Sniper® Spine System has quickly developed a reputation as a leading MIS screw system and the recently enhanced CapSure® PS3 Spine System is proving to be a high quality, traditional screw system with an expanded offering for complex surgery. The Company continues to advance the NuCore® Injectable Nucleus technology in a European clinical study designed to treat early stage DDD via a percutaneous injection. For further information on all of the Spine Wave products please visit the Company's website at www.SpineWave.com.


Contact:
Terry Brennan
Chief Financial Officer
Email Contact
203-712-1810



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->